Ravidasvir
Ravidasvir (PPI-668) is an orally active pan-genotypic NS5A inhibitor and antiviral agent. Ravidasvir exhibits antiviral activity against HCV genotypes 1 to 6, with EC50 values ranging from 0.04 to 1.14 nM. Ravidasvir shows no or extremely low activity against feline infectious peritonitis virus type II. Ravidasvir can be used in research related to hepatitis C virus infection.
For research use only. We do not sell to patients.
- CAS No.: 1242087-93-9
- Formula: C42H50N8O6
- Molecular Weight:762.91
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7 | EC50 |
0.007 nM
Compound: 25
|
Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay
Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay
|
[PMID: 24320933] |
| Huh-7 | EC50 |
0.071 nM
Compound: 25
|
Antiviral activity against HCV genotype 1a H77 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay
Antiviral activity against HCV genotype 1a H77 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay
|
[PMID: 24320933] |
In Vitro
Ravidasvir potently inhibits HCV genotypes 1 to 6 with EC50 values of 0.04 to 1.14 nM[2].
Ravidasvir (10 μM; 72 h) exhibits absent-to-minimal anti-FIPV serotype II activity and causes cytotoxicity at 10 μM in CRFK cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | AUC0-24 | AUC0-∞ | Cmax | Tmax | T1/2 | MRT0-∞ | CL/F |
|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 35 mg/kg | p.o. | 811.25 ng·h/mL | 893.09 ng·h/mL | 132.35 ng/mL | 4.00 h | 3.24 h | 5.56 h | 0.0419 |
Chemical Information
-
CAS No. 1242087-93-9
-
Molecular Weight 762.91
-
Formula C42H50N8O6
-
SMILES
C([C@@H](NC(OC)=O)C(C)C)(=O)N1[C@H](C=2NC=3C(N2)=CC=C(C3)C4=CC5=C(C=C4)C=C(C=C5)C=6NC(=NC6)[C@H]7N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC7)CCC1
-
Synonyms
PPI-668
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Zymosan-Induced Peritonitis
Zymosan-induced peritonitis is a sterile acute-inflammation model produced by intraperitoneal injection of zymosan, a yeast cell-wall particle preparation, followed by quantification of leukocyte recruitment and soluble inflammatory mediators in peritoneal lavage fluid. Low-dose zymosan peritonitis is commonly used as a self-resolving acute inflammation model in which neutrophil recruitment occurs early and monocyte/macrophage accumulation follows later. The assay readouts include total peritoneal leukocyte number, differential neutrophil and monocyte/macrophage counts, peritoneal cytokines and chemokines, plasma or peritoneal exudation, and optional lipidomic or metabolomic changes during inflammation and resolution. Early neutrophil recruitment after zymosan depends strongly on complement and mast-cell C5a receptor signaling, whereas later monocyte recruitment is linked to MCP-1/CCL2 production.
Purity & Documentation
References
[1]. Hefnawy M, et al. Validated Microwell-Based Spectrofluorimetric Method for Quantification of Ravidasvir (New Anti-Chronic Hepatitis C Virus-GT4) in Rat Plasma and Its Application to Pharmacokinetic Study. Drug Des Devel Ther. 2020;14:4377-4385. Published 2020 Oct 20. [Content Brief]
[2]. Wu G, et al. Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects. Antimicrob Agents Chemother. 2021;65(10):e0060021. [Content Brief]
[3]. Cook SE, et al. Investigation of monotherapy and combined anticoronaviral therapies against feline coronavirus serotype II in vitro. J Feline Med Surg. 2022;24(10):943-953. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)